15 Results for "

Hypoxia-inducible factor-2

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "Hypoxia-inducible factor-2" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-139287
CAS No.: 823830-85-9
Purity:  99.69%
Research Areas:  

Cancer

M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136748
CAS No.: 882268-69-1
Purity:  99.96%
Research Areas:  

Cancer

HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC50 of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .
loading...
    loading...
Cat. No.: HY-159644
CAS No.: 2709069-30-5
Synonyms: AB521
Research Areas:  

Cancer

Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .
loading...
    loading...
Cat. No.: HY-111547
CAS No.: 874590-32-6
Purity:  99.51%
Research Areas:  

Cancer

M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 can be used in chronic kidney disease research .
loading...
    loading...
Cat. No.: HY-147426
CAS No.: 2437257-11-7
Synonyms: ADS-007; ARO HIF2
Zifcasiran (ADS-007; ARO HIF2) is an siRNA synthetic double-stranded RNAi trigger. Zifcasiran sodium selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). Zifcasiran sodium engages the cell's RNAi machinery to target HIF2α (EPAS1) mRNA for degradation, thereby reducing the amount of free HIF2α mRNA available for translation .
loading...
    loading...
Cat. No.: HY-108697A
CAS No.: 1672662-07-5
Purity:  99.84%
Research Areas:  

Cancer

(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM .
loading...
    loading...
Cat. No.: HY-147426A
CAS No.: 2437257-12-8
Synonyms: ADS-007 sodium; ARO HIF2 sodium
Zifcasiran (ADS-007) sodium is an siRNA synthetic double-stranded RNAi trigger. Zifcasiran sodium selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). Zifcasiran sodium engages the cell's RNAi machinery to target HIF2α (EPAS1) mRNA for degradation, thereby reducing the amount of free HIF2α mRNA available for translation .
loading...
    loading...
Cat. No.: HY-18370
CAS No.: 313964-19-1
Research Areas:  

Cancer

HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC50 of 0.4 µM and a KD of 1.1 µM. Anticancer agent .
loading...
    loading...
Cat. No.: HY-148264
CAS No.: 2511247-29-1
Synonyms: HIF-2α-IN-7; NKT2152
Imdatifan (HIF-2α-IN-7) is a hypoxia inducible factor 2α (HIF-2α) inhibitor. Imdatifan can inhibit HIF-2α with an EC50 value of 6 nM. Imdatifan can be used for the research of various types of diseases including cancer, liver disease, inflammatory disease, pulmonary diseases and iron load disorders .
loading...
    loading...
Cat. No.: HY-121728
CAS No.: 1370510-16-9
Target:  

Others

Research Areas:  

Others

Langkamide is a novel hypoxia-inducible factor-2 (HIF-2) inhibitory pyrrolidone alkaloid isolated from the roots and stems of Piper sarmentosum, which inhibits HIF-2 transcriptional activity with an EC value of 14.0μM.
loading...
    loading...
Cat. No.: HY-P81153
Synonyms: Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_HUMAN; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; Hypoxia inducible factor 2 alpha; Hypoxia inducible factor 2 alpha subunit; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.

Host:  

Rabbit

Application:  

WB, IHC-P, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-111547R
CAS No.: 874590-32-6
Research Areas:  

Cancer

M1001 (Standard) is the analytical standard of M1001 (HY-111547). This product is intended for research and analytical applications. M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 can be used in chronic Kidney disease research .
loading...
    loading...
Cat. No.: HY-108697AR
CAS No.: 1672662-07-5
Research Areas:  

Cancer

(Rac)-PT2399 (Standard) is the analytical standard of (Rac)-PT2399 (HY-108697A). This product is intended for research and analytical applications. (Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM .
loading...
    loading...
Cat. No.: HY-W470101
CAS No.: 861212-49-9
Research Areas:  

Cancer

HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-179647
CAS No.: 1795110-22-3
ZG-2686 is a potent and selective HIF-2α agonist with an EC50 of 0.25 µM. ZG-2686 exhibits selectivity over PHD2. ZG-2686 binds to a specific internal cavity of HIF-2α, forming hydrogen bonds via structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances transcriptional activity. ZG-2686 synergizes with Vadadustat (HY-101277) to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 can be used for the research of renal anemia .
loading...
    loading...
  • 1